Detrusor-Sphincter Dyssynergia: An Off-Label Alpha-Blocker Instead of Catheterization
A man voiding on his own but emptying poorly wants to avoid starting intermittent catheterization. The alternative on the table has almost no trial support and no label for what he actually has.
Sam R., a 37-year-old high school shop teacher who still demonstrates every power-tool technique himself rather than just describing it, sustained an incomplete T12 spinal cord injury four years ago in a fall from a ladder and has remained ambulatory with forearm crutches since, a fact he brings up before almost anything else about his own case. He voids volitionally without ever having needed to catheterize, a point of real pride he's stated outright more than once, but urodynamic testing after his second urinary tract infection this year confirmed detrusor-sphincter dyssynergia — his bladder and urethral sphincter contracting at the same time instead of in sequence, leaving him emptying incompletely no matter how hard or how long he tries. His third infection in eight months, culture-confirmed this week, has made the team unwilling to simply keep treating infections as they come.
His post-void residual on repeat testing runs 220mL against a voided volume of only 140mL — he is retaining more urine after voiding than he successfully expels, the actual mechanical reason recurrent infection keeps finding a reservoir to grow in regardless of which antibiotic clears the current one. Tamsulosin carries no labeled indication for detrusor-sphincter dyssynergia, and the trial record is thinner than its reputation. Abrams et al. randomized 263 patients with suprasacral spinal cord injury, mean age in the mid-thirties, to placebo or tamsulosin for four blinded weeks, and the blinded phase did not reach statistical significance against placebo on its primary endpoint, maximum urethral pressure; the drop was larger on drug than on placebo, but not significantly so. The encouraging figures usually quoted from that study come from the uncontrolled year of open-label treatment that followed it, in the 186 patients who chose to continue. At 37 with a suprasacral lesion, Sam sits squarely inside the population that trial enrolled, which is the difficulty rather than the reassurance: the result does describe him, and the randomized half of it is a null.
Urology clinic, third UTI this year
I'd offer him a trial of tamsulosin before recommending intermittent catheterization, and I'll concede the weak part of my own case first: Abrams' randomized phase missed its primary endpoint. But 186 of those patients elected to continue into a year of open-label therapy and their storage and emptying measures improved over it, which is not nothing in a condition that has no approved drug at all. A lower residual could plausibly break the infection cycle without asking him to give up something he's clearly built real identity around.
I appreciate the concession, but I don't think it goes far enough.
An open-label year in the patients who stayed on the drug is the design that manufactures improvement most reliably — the fifty-eight who finished the blinded phase and declined to continue don't appear in that number. The randomized comparison was the only part of that study built to answer the question we're asking, and it answered it in the negative. Three culture-confirmed infections in eight months is a real, recurring harm happening now; I'd rather start CIC today, which reliably fixes incomplete emptying, than spend four more weeks on a drug whose controlled evidence in his exact population is a null result.
Both of you are right about the evidence and both underweight what walking without a catheter is worth to Sam specifically. I'd offer the tamsulosin trial with a firm, pre-agreed endpoint — a repeat post-void residual at four weeks — rather than an open-ended attempt.
If his residual hasn't meaningfully improved by then, we move to CIC without further delay and without treating the trial as a failure on his part. That gives the evidence a real chance to apply to him specifically, on a timeline that doesn't let his infection risk run unchecked.
Agreed: tamsulosin 0.4mg trial with a firm four-week post-void residual recheck as the explicit decision point for whether to continue the alpha-blocker or begin CIC.
Not agreed: the infectious disease physician would have started CIC today given the recurring, active infection risk, and views the four-week trial as accepting a known ongoing harm for a benefit whose only controlled test came back null — recorded explicitly rather than resolved, since Sam's own preference, and not the strength of the evidence, is what persuaded the rest of the team to give the drug one bounded attempt first.